{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:37:47Z","timestamp":1783366667489,"version":"3.54.6"},"reference-count":17,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>We report on a former 27-week gestational age infant who was placed on the Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIEM) at 4 months post-menstrual age while receiving cefepime treatment for an <jats:italic>Enterobacter cloacae<\/jats:italic> bacteremia and persistent peritonitis secondary to an infected peritoneal dialysis catheter. Using therapeutic drug monitoring while assessing the clearance of cefepime on continuous renal replacement therapy (CRRT), we were able to successfully treat this patient's infection while also minimizing the risk of side effects from this medication. Current literature supports dosing in adult patients on all modalities of CRRT with effluent flow rates of 20 to 25 mL\/kg\/hr; however, pharmacokinetic data on cefepime dosing in pediatric CRRT are scant. This case report describes the successful dosing strategy used for this patient while on various rates of continuous veno-venous hemodialysis with CARPEDIEM. Therapeutic drug monitoring of cefepime should be considered in critically ill pediatric patients on CARPEDIEM receiving CRRT.<\/jats:p>","DOI":"10.5863\/1551-6776-28.2.167","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:32:49Z","timestamp":1682523169000},"page":"167-171","source":"Crossref","is-referenced-by-count":1,"title":["Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy With the Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIEM)"],"prefix":"10.5863","volume":"28","author":[{"given":"Cynthia","family":"Toy","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services (CT, GS, MM), Texas Children's Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Stimes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services (CT, GS, MM), Texas Children's Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services (CT, GS, MM), Texas Children's Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poyyapakkam","family":"Srivaths","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Renal Section (PS, AAA), Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Akcan","family":"Arikan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Renal Section (PS, AAA), Baylor College of Medicine, Houston, TX"},{"name":"Department of Pediatrics, Section of Critical Care Medicine (AAA), Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"9931","key":"i2331-348X-28-2-167-b1","series-title":"Lancet","first-page":"1807","article-title":"Continuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM)","volume":"383","year":"2014","unstructured":"Ronco\n              C\n            ,\n\t\t\t\t\t\tGarzottoF,\n\t\t\t\t\t\tBrendolanA,\n\t\t\t\t\t\n          .\n\t\t\t\t\tContinuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM).\n\t\t\t\t\tLancet.\n\t\t\t\t\t2014;383(9931):1807\u20131813."},{"key":"i2331-348X-28-2-167-b2","series-title":"FDA Grants Marketing of New Device for Continuous Dialysis Therapy for Use in Pediatric Patients with Certain Kidney Conditions","article-title":"Center for Drug Evaluation and Research (2020)","year":"2021","unstructured":"US Food and Drug Administration.\n\t\t\t\t\t\n          Center for Drug Evaluation and Research (2020).\n\t\t\t\t\tFDA Grants Marketing of New Device for Continuous Dialysis Therapy for Use in Pediatric Patients with Certain Kidney Conditions.\n\t\t\t\t\tWashington, DC:\n\t\t\t\t\tAlison Hunt;\n\t\t\t\t\t2021."},{"key":"i2331-348X-28-2-167-b3","series-title":"Scand J Infect Dis Suppl","first-page":"63","article-title":"Killing and regrowth of bacteria in vitro: a review","volume":"74","year":"1990","unstructured":"Craig\n              WA\n            ,\n\t\t\t\t\t\tEbertSC.\n          Killing and regrowth of bacteria in vitro: a review.\n\t\t\t\t\tScand J Infect Dis Suppl.\n\t\t\t\t\t1990;74:63\u201370."},{"issue":"3","key":"i2331-348X-28-2-167-b4","series-title":"J Antimicrobl Chemother","first-page":"425","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","year":"2002","unstructured":"Tam\n              VH.\n            \n          \n          Pharmacodynamics of cefepime in patients with Gram-negative infections.\n\t\t\t\t\tJ Antimicrobl Chemother.\n\t\t\t\t\t2002;50(3):425\u2013428."},{"issue":"5","key":"i2331-348X-28-2-167-b5","series-title":"Antimicrob Agents Chemother","first-page":"931","article-title":"Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model","volume":"38","year":"1994","unstructured":"Mouton\n              JW\n            ,\n\t\t\t\t\t\tden HollanderJG.\n          Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t1994;38(5):931\u2013936."},{"issue":"4","key":"i2331-348X-28-2-167-b6","series-title":"Antimicrob Agents Chemother","first-page":"e02006","article-title":"Cefepime pharmacokinetics in critically ill pediatric patients receiving continuous renal replacement therapy","volume":"63","year":"2019","unstructured":"Stitt\n              G\n            ,\n\t\t\t\t\t\tMorrisJ,\n\t\t\t\t\t\tSchmeesL,\n\t\t\t\t\t\n          .\n\t\t\t\t\tCefepime pharmacokinetics in critically ill pediatric patients receiving continuous renal replacement therapy.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2019;63(4):e02006\u2013e02018."},{"issue":"3","key":"i2331-348X-28-2-167-b7","series-title":"Pediatr Blood Cancer","first-page":"379","article-title":"Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population","volume":"53","year":"2009","unstructured":"Courter\n              JD\n            ,\n\t\t\t\t\t\tKutiJL,\n\t\t\t\t\t\tGirottoJE,\n\t\t\t\t\t\tNicolauDP.\n          Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.\n\t\t\t\t\tPediatr Blood Cancer.\n\t\t\t\t\t2009;53(3):379\u2013385."},{"issue":"1","key":"i2331-348X-28-2-167-b8","series-title":"Paediatr Drugs","first-page":"45","article-title":"Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients","volume":"6","year":"2004","unstructured":"Veltri\n              MA\n            ,\n\t\t\t\t\t\tNeuAM,\n\t\t\t\t\t\tFivushBA,\n\t\t\t\t\t\n          .\n\t\t\t\t\tDrug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients.\n\t\t\t\t\tPaediatr Drugs.\n\t\t\t\t\t2004;6(1):45\u201365."},{"issue":"88","key":"i2331-348X-28-2-167-b9","series-title":"Antimicrobial Agents Chemother","first-page":"1783","article-title":"Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children","volume":"41","year":"1997","unstructured":"Reed\n              MD\n            ,\n\t\t\t\t\t\tYamashitaTS,\n\t\t\t\t\t\tKnuppCK,\n\t\t\t\t\t\n          .\n\t\t\t\t\tPharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.\n\t\t\t\t\tAntimicrobial Agents Chemother.\n\t\t\t\t\t1997;41(88):1783\u20131787."},{"issue":"3","key":"i2331-348X-28-2-167-b10","series-title":"Pediatr Infect Dis J","first-page":"337","article-title":"Review of the pharmacokinetics of cefepime in children","volume":"20","year":"2001","unstructured":"Blumer\n              JL\n            ,\n\t\t\t\t\t\tReedMD,\n\t\t\t\t\t\tKnuppC.\n          Review of the pharmacokinetics of cefepime in children.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2001;20(3):337\u2013342."},{"issue":"11","key":"i2331-348X-28-2-167-b11","series-title":"Antimicrob Agents Chemother","first-page":"2424","article-title":"Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration","volume":"41","year":"1997","unstructured":"Allaouchiche\n              B\n            ,\n\t\t\t\t\t\tBreilhD,\n\t\t\t\t\t\tJaumainH,\n\t\t\t\t\t\n          .\n\t\t\t\t\tPharmacokinetics of cefepime during continuous venovenous hemodiafiltration.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t1997;41(11):2424\u20132427."},{"issue":"11","key":"i2331-348X-28-2-167-b12","series-title":"Antimicrob Agents Che-mother","first-page":"3148","article-title":"Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients","volume":"45","year":"2001","unstructured":"Malone\n              RS\n            ,\n\t\t\t\t\t\tFishDN,\n\t\t\t\t\t\tAbrahamE,\n\t\t\t\t\t\n          .\n\t\t\t\t\tPharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.\n\t\t\t\t\tAntimicrob Agents Che-mother.\n\t\t\t\t\t2001;45(11):3148\u20133155."},{"issue":"3","key":"i2331-348X-28-2-167-b13","series-title":"Crit Care","first-page":"R105","article-title":"B-lactam antibiotic concentrations during continuous renal replacement therapy","volume":"18","year":"2014","unstructured":"Beumier\n              M\n            ,\n\t\t\t\t\t\tCasuGS,\n\t\t\t\t\t\tHitesM,\n\t\t\t\t\t\n          .\n\t\t\t\t\tB-lactam antibiotic concentrations during continuous renal replacement therapy.\n\t\t\t\t\tCrit Care.\n\t\t\t\t\t2014;18(3):R105."},{"issue":"1","key":"i2331-348X-28-2-167-b14","series-title":"J Intensive Care","first-page":"61","article-title":"Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study","volume":"6","year":"2018","unstructured":"Chaijamorn\n              W\n            ,\n\t\t\t\t\t\tCharoensareeratT,\n\t\t\t\t\t\tSrisawatN,\n\t\t\t\t\t\n          .\n\t\t\t\t\tCefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.\n\t\t\t\t\tJ Intensive Care.\n\t\t\t\t\t2018;6(1):61."},{"issue":"7","key":"i2331-348X-28-2-167-b15","series-title":"Medicine (Baltimore)","first-page":"e46","article-title":"High phenobarbital clearance during continuous renal replacement therapy: a case report and pharmacokinetic analysis","volume":"93","year":"2014","unstructured":"Rosenborg\n              S\n            ,\n\t\t\t\t\t\tSarasteL,\n\t\t\t\t\t\tWideK.\n          High phenobarbital clearance during continuous renal replacement therapy: a case report and pharmacokinetic analysis.\n\t\t\t\t\tMedicine (Baltimore).\n\t\t\t\t\t2014;93(7):e46."},{"issue":"2","key":"i2331-348X-28-2-167-b16","series-title":"Crit Care","first-page":"R51","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","year":"2010","unstructured":"Chapuis\n              TM\n            ,\n\t\t\t\t\t\tGiannoniE,\n\t\t\t\t\t\tMajcherczykPA,\n\t\t\t\t\t\n          .\n\t\t\t\t\tProspective monitoring of cefepime in intensive care unit adult patients.\n\t\t\t\t\tCrit Care.\n\t\t\t\t\t2010;14(2):R51."},{"issue":"3","key":"i2331-348X-28-2-167-b17","series-title":"A retrospective cohort study. Clin Microbiol Infect","first-page":"333","article-title":"Cefepime neurotoxicity: thresholds and risk factors","volume":"26","year":"2020","unstructured":"Boschung-Pasquier\n              L\n            ,\n\t\t\t\t\t\tAtkinsonA,\n\t\t\t\t\t\tKastnerLK,\n\t\t\t\t\t\n          .\n\t\t\t\t\tCefepime neurotoxicity: thresholds and risk factors.\n\t\t\t\t\tA retrospective cohort study. Clin Microbiol Infect.\n\t\t\t\t\t2020;26(3):333\u2013339."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/2\/article-p167.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/2\/167\/3213224\/i2331-348x-28-2-167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/2\/article-p167.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/2\/article-p167.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:48:12Z","timestamp":1747356492000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/2\/article-p167.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":17,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.2.167","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}